Additionally, the 36-month beta value for RNAZ is 1.53. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for RNAZ is 20.98M and currently, short sellers hold a 4.95% ratio of that float. The average trading volume of RNAZ on April 28, 2025 was 7.60M shares.
RNAZ) stock’s latest price update
TransCode Therapeutics Inc (NASDAQ: RNAZ)’s stock price has plunge by -5.00relation to previous closing price of 0.40. Nevertheless, the company has seen a 39.45% surge in its stock price over the last five trading sessions. prnewswire.com reported 2025-04-21 that BOSTON, April 21, 2025 /PRNewswire/ — TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced its Special Meeting scheduled for and convened on April 21, 2025, (the “Special Meeting”) has been adjourned until May 2, 2025, at 9:30 a.m. Eastern time (the “Adjourned Special Meeting”) for the purpose of soliciting additional votes with respect to the proposals outlined below and described in the Company’s definitive proxy statement for the Special Meeting filed with the Securities and Exchange Commission (the “SEC”) on April 11, 2025 (the “Special Meeting Proxy Statement”).
RNAZ’s Market Performance
RNAZ’s stock has risen by 39.45% in the past week, with a monthly drop of -35.59% and a quarterly drop of -94.60%. The volatility ratio for the week is 28.46% while the volatility levels for the last 30 days are 23.54% for TransCode Therapeutics Inc The simple moving average for the last 20 days is -6.56% for RNAZ stock, with a simple moving average of -95.97% for the last 200 days.
RNAZ Trading at -82.20% from the 50-Day Moving Average
After a stumble in the market that brought RNAZ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.43% of loss for the given period.
Volatility was left at 23.54%, however, over the last 30 days, the volatility rate increased by 28.46%, as shares sank -26.92% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -96.47% lower at present.
During the last 5 trading sessions, RNAZ rose by +39.45%, which changed the moving average for the period of 200-days by -98.65% in comparison to the 20-day moving average, which settled at $0.4068. In addition, TransCode Therapeutics Inc saw -88.72% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for RNAZ
The total capital return value is set at -3.47. Equity return is now at value -490.03, with -268.85 for asset returns.
Based on TransCode Therapeutics Inc (RNAZ), the company’s capital structure generated -0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -348.28. The debt to equity ratio resting at -0.02. The interest coverage ratio of the stock is -585.5.
Currently, EBITDA for the company is -14.03 million with net debt to EBITDA at 0.36. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.56.
Conclusion
In conclusion, TransCode Therapeutics Inc (RNAZ) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
